AI Patent Analysis Toolkit
PatentAgility
by KellDann

Examiner Bo Peng, Ph.D

Appears inactive Last observed office action: January 2012 (173 months ago).

Examiner Bo Peng, Ph.D appears to be about average relative to their peer examiners. Their lifetime grant ratio is 44.7%, they average 1.68 office actions per granted patent, and their rejection profile leans toward ยง103.

Difficulty vs AU About Average
Difficulty vs Group About Average
Difficulty vs TC Very Easy
Difficulty vs USPTO About Average
Average OA / Grant 1.68
Export
Word PDF

Create account to export.

Examiner Details

Observed Examiner Years
5 years (2008-2012)
Tech Center
1600 - Biotechnology and Organic
Group
1640 - Immunology

Metrics

Applications Evaluated
152
Granted Applications
68
Non-Granted Applications
84
Avg OA / Grant
1.68
Last OA Observed
January 2012 (173 months ago)
Art Units Seen
1648
Work Groups Seen

Context Comparison

Scope Examiners Lifetime Grant Ratio Avg OA / Grant
This Examiner 1 44.7% 1.68
Art Unit 24 56.7% 1.92
Group 223 44.8% 1.94
Tech Center 1,349 39.5% 2.02
USPTO 16,116 54.8% 1.98

Grant Timeline

0.0% 25.0% 50.0% 75.0% 100.0% 2008 2009 2010 2011 2012
Shaded region marks the last two observed years, where grant outcomes may lag due to recency.
Year Applications Granted Grant Rate
No observed data before 2008; examiner may not yet have been active in the available dataset.
2008 23 8 34.8%
2009 46 22 47.8%
2010 42 19 45.2%
2011 40 18 45.0%
2012 1 1 100.0%
No observed data after 2012; examiner may have gone inactive or moved out of examining work.

68 family-cache-validated grants; 0 OA-only grant signals.

Rejection Timeline

OA # Office Actions § 101 Percentage § 102 Percentage § 103 Percentage § 112 Percentage
1 152 0.7% 9.9% 42.1% 9.9%
2 76 0.0% 6.6% 44.7% 9.2%
3 21 0.0% 14.3% 52.4% 4.8%
4 4 0.0% 0.0% 75.0% 0.0%
5 1 0.0% 0.0% 100.0% 0.0%

§ 101 Yearly Trend

0.0%
2008
1.2%
2009
0.0%
2010
0.0%
2011
0.0%
2012

Each bar shows the share of this examiner's observed office actions in that year that included a § 101 rejection.